scholarly journals Synergistically Active and Safe Fixed Dose Combination of Meropenem and Sulbactam

IIOAB Letters ◽  
2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Vijender Singh Beniwal ◽  
Parmjit Arora
Keyword(s):  
Antimicrobial Activity ◽  
Wistar Rats ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Synergistic Activity ◽  
Mutant Plasmid ◽  
Broad Spectrum Antibiotic ◽  
Subchronic Toxicity ◽  
Dose Combination ◽  
Lactamase Inhibitor

Meropenem is a third generation broad spectrum antibiotic. Emergence of meropenem resistance has been reported due to development of mutant plasmid mediated metallo-β-lactamases (IMP-6) and AmpC β–lactamases. Sulbactam, a stable β-lactamase inhibitor, increase antimicrobial activity of meropenem by inhibiting the enzyme β-lactamase. Fixed dose combination of Meropenem-sulbactam in the proportion of 1:1, 1:2, 1:3, 2:1 and 3:1 were evaluated for the antimicrobial activity. Combination of meropenem and sulbactam in the ratio of 2:1 exhibited the synergistic activity. This combination was checked for the subchronic toxicity on wistar rats and no change in biochemical and physiological parameters was observed.

Comparative In Vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection

2009 ◽  
Vol 4 (2) ◽  
pp. 106-110
Author(s):  
Dharmendra Rai ◽  
Vivek Dwivedi ◽  
Manu Chaudhary ◽  
Sanjay Shrivastava ◽  
Praveen Rishi ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Helicobacter Pylori ◽  
Helicobacter Pylori Infection ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
In Vitro Antimicrobial Activity ◽  
Dose Combination

Fixed dose combination therapy loperamide and niacin ameliorates diethylnitrosamine-induced liver carcinogenesis in albino Wistar rats

RSC Advances ◽  
2015 ◽  
Vol 5 (83) ◽  
pp. 67996-68002 ◽  
Author(s):  
Ruqaiyah Khan ◽  
Imran Kazmi ◽  
Muhammad Afzal ◽  
Fahad A. Al Abbasi ◽  
Gohar Mushtaq ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Wistar Rats ◽  
Survival Rates ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Liver Carcinogenesis ◽  
The Third ◽  
Dose Combination

Hepatocellular carcinoma (HCC) is among the most lethal cancers (five-year survival rates under 11%), which makes it the third most frequent cause of cancer related deaths in men and sixth in women.

Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
ED Bateman ◽  
K Chapman ◽  
S Rennard ◽  
L Rekeda ◽  
M Moya ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Dose Combination

Overall safety and cardiovascular safety of fixed-dose combination of aclidinium/formoterol compared to salmeterol/fluticasone in patients with COPD

Pneumologie ◽  
2016 ◽  
Vol 70 (S 01) ◽  
Author(s):  
J Beier ◽  
C Vogelmeier ◽  
R Mroz ◽  
S Pascual ◽  
RM Segarra ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Cardiovascular Safety ◽  
Dose Combination

135-OR: The Effect of Fixed-Dose Combination of Insulin Degludec and Liraglutide on Serum Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 135-OR
Author(s):  
ELENI PAPPA ◽  
CHRISTINA KOSTARA ◽  
CONSTANTINOS TELLIS ◽  
ALEXANDROS D. TSELEPIS ◽  
ELENI BAIRAKTARI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipoprotein Metabolism ◽  
Serum Lipoprotein ◽  
Insulin Degludec ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document